Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment…

Lymphoplasmacytic LymphomaCancerProcedureDrugBiologicalPhase 2

RecruitingPhase 2

Lymphoplasmacytic LymphomaCancerProcedureDrugBiologicalPhase 2

NCT04840602

Comparing venetoclax with rituximab and ibrutinib with rituximab or zanubrutinib for untreated Waldenström's macroglobulinemia

Our summary — not written by the study team

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma · National Cancer Institute (NCI)

Do you qualify?

34 criteria to check

Time: Followed for up to 5 years
When the study takes its last measurement. Ask the team for the full schedule. Study record
Pay: Travel costs may be covered
Sponsor hasn't indicated
An estimate, not an offer. Confirm with the study team. Saturn's Estimate

106 open sites · Tucson, Arizona · 105 more

What this study is

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib, a type of tyrosine kinase inhibitor, blocks a protein called BTK, which may help keep cancer cells from growing. Giving venetoclax and rituximab may work better in treating patients with previously untreated Waldenstrom's macroglobulinemia than ibrutinib with rituximab or zanubrutinib alone.

What's being tested

Biospecimen Collection
Intervention · PROCEDURE
Undergo blood sample collection
Bone Marrow Aspiration
Intervention · PROCEDURE
Bone Marrow Biopsy
Intervention · PROCEDURE
Computed Tomography
Intervention · PROCEDURE
Undergo CT or PET/CT
Ibrutinib
Intervention · DRUG
Positron Emission Tomography
Intervention · PROCEDURE
Undergo PET/CT
Rituximab
Intervention · BIOLOGICAL
Given IV
Venetoclax
Intervention · DRUG
Zanubrutinib
Intervention · DRUG

Both Bone Marrow Aspiration and Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

All of Ibrutinib, Venetoclax, Zanubrutinib

Given PO

Study details

Official title: A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
Sponsor: National Cancer Institute (NCI)
Conditions: Lymphoplasmacytic Lymphoma · Waldenstrom Macroglobulinemia
Enrolling: 92 people
Starts: 2022-01-05
Est. completion: 2028-03-31
Design: Open-label, randomized, crossover, Phase 2
Record: View on ClinicalTrials.gov ↗

Who can join

Age 18 Years and overSex ALLHealthy volunteers Not accepted

You may qualify if

Participants must have had a confirmed diagnosis of Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL). Participants must have measurable disease as determined by IgM protein quantification.; IgM Spike: ≥ 500 mg/dL (≥ 5 g/L); Extramedullary disease: The manifestation of a lymphoid mass outside of the bone marrow, resulting in enlargement in extramedullary organs such as the lymph nodes or spleen. Note: all participants must have measurable IgM spike, but are not required to have extramedullary disease
Testing to establish baseline disease status must be performed within 28 days prior to registration
Participants must have at least one of the criteria to require therapy for WM including:; Anemia; Thrombocytopenia; Neuropathy related to WM; Symptomatic hyperviscosity or serum viscosity levels ≥ 4.0 centipoises; WM associated glomerulonephritis or renal disease, bulky disease, or constitutional symptoms; Constitutional symptoms can be described as:; Unintentional weight loss >= 10% within the previous 6 months prior to screening; Fevers higher than 100.5 degrees Fahrenheit (F) or 38.0 degrees Celsius (C) for 2 or more weeks prior to screening without evidence of infection; Night sweats for more than 1 month prior to screening without evidence of infection; Clinically relevant fatigue which is not relieved by rest due to WM
Participants who require ongoing use or received a moderate or strong CYP3A inducer, moderate or strong CYP3A inhibitor, P-gp inhibitor within 7 days prior to the first dose of study drug will be excluded from the study. If such participants can be safely switched to an alternative agent, then the participants will be eligible to enroll
Participants must not have had prior systemic therapy. Prior therapy with rituximab will be allowed as long as the last rituximab dose was at least 6 months prior to registration
Participants must be >= 18 years of age
Participants must have history and physical exam within 28 days prior to registration
Participants must have Zubrod performance status =< 2
Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) >= 30 mL/min. Values must be obtained within 14 days prior to registration
Total bilirubin =< 1.5 x IULN (institutional upper limit of the norm) (within 14 days prior to registration)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x IULN (within 14 days prior to registration)
Alkaline phosphatase =< 3 x IULN (within 14 days prior to registration)
Platelet count >= 50,000 cells/mm^3 (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
Hemoglobin >= 7.0 g/dL (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration
Participants must be able to take and swallow oral medication (capsules) whole. Participants may not have any known impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
Participants must not be intolerant to rituximab
Participants must not have known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding localized skin and nail bed fungal infections) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) 4 weeks prior to registration
Participants must not be seropositive for hepatitis C (except in the setting of sustained virologic response, defined as undetectable viral load at least 12 weeks after completion of antiviral therapy). Hepatitis C virus (HCV) testing is only required if clinically indicated or if the participant has a history of HCV
Participants must not consume grapefruit, Seville oranges or starfruit within 3 days prior to the first dose of venetoclax
Participants must not be pregnant or nursing because venetoclax has not been studied in pregnant or nursing women and the mechanism of action is expected to cause fetal harm. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condom, cervical ring, sponge, etc.). This also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures throughout the study and for at least 30 days after competition of therapy
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years or watchful waiting is appropriate in the opinion of the treating physician. Also, malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 5 years, is permissible consideration of eligibility for this trial
Participants must be offered the opportunity to participate in specimen banking
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
As a part of the Oncology Participant Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
CROSSOVER CRITERIA: Participants must have been registered and received treatment in the IR/Z or VR arm and must show progression of disease at any time during cycles 3-24
CROSSOVER CRITERIA: In case of transformation to intermediate or high-grade lymphoma or development of Bing-Neel syndrome the participants will not undergo registration step 2 crossover and will be taken off the study
CROSSOVER CRITERIA: Participants must have Zubrod performance status =< 2
CROSSOVER CRITERIA: Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) >= 30 mL/min. Values must be obtained within 14 days prior to registration
CROSSOVER CRITERIA: Participants must have no evidence of marked hepatic dysfunction on any recent liver function tests within 14 days prior to registration
CROSSOVER CRITERIA: Platelet count >= 50,000 cells/mm^3 (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
CROSSOVER CRITERIA: Hemoglobin >= 7.0 g/dL (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
CROSSOVER CRITERIA: Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration

Study locations (150)

106 open

Banner University Medical Center - Tucson
Tucson, Arizona, United States
- ContactUACC-IIT@uacc.arizona.edu
- Muhammad Husnain · Principal investigator
Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
- ContactUACC-IIT@uacc.arizona.edu
- Muhammad Husnain · Principal investigator
Recruiting
City of Hope at Irvine Lennar
Irvine, California, United States
- Contact877-467-3411
- Benjamin M. Heyman · Principal investigator
Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
- Contact305-243-2647
- Georgios Pongas · Principal investigator
Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida, United States
- Contact305-243-2647
- Georgios Pongas · Principal investigator
Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
- Contact305-243-2647
- Georgios Pongas · Principal investigator
Recruiting
UM Sylvester Comprehensive Cancer Center at Doral
Doral, Florida, United States
- Contactkginnity@med.miami.edu
- Georgios Pongas · Principal investigator
Recruiting
UM Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, Florida, United States
- Contact305-243-2647
- Georgios Pongas · Principal investigator
Recruiting
Mayo Clinic in Florida
Jacksonville, Florida, United States
- Contact855-776-0015
- Sikander Ailawadhi · Principal investigator
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Contact305-243-2647
- Georgios Pongas · Principal investigator
Recruiting
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
- Contact305-243-2647
- Georgios Pongas · Principal investigator
Recruiting
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
North Miami, Florida, United States
- Contactkginnity@med.miami.edu
- Georgios Pongas · Principal investigator
Recruiting
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Contact305-243-2647
- Georgios Pongas · Principal investigator
Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
- Contact734-712-3671 stephanie.couch@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States
- Contact734-712-3671 stephanie.couch@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Idaho Urologic Institute-Meridian
Meridian, Idaho, United States
- Contact734-712-3671 stephanie.couch@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, United States
- Contact406-969-6060 mccinfo@mtcancer.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Centralia Oncology Clinic
Centralia, Illinois, United States
- Contact217-876-4762 morganthaler.jodi@mhsil.com
- Bryan A. Faller · Principal investigator
Recruiting
Carle at The Riverfront
Danville, Illinois, United States
- Contact800-446-5532 Research@Carle.com
- Priyank P. Patel · Principal investigator
Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, United States
- Contact217-876-4762 morganthaler.jodi@mhsil.com
- Bryan A. Faller · Principal investigator
Recruiting
Carle Physician Group-Effingham
Effingham, Illinois, United States
- Contact800-446-5532 Research@carle.com
- Priyank P. Patel · Principal investigator
Recruiting
Crossroads Cancer Center
Effingham, Illinois, United States
- Contact217-876-4762 morganthaler.jodi@mhsil.com
- Bryan A. Faller · Principal investigator
Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, United States
- Contact800-446-5532 Research@carle.com
- Priyank P. Patel · Principal investigator
Recruiting
Loyola University Medical Center
Maywood, Illinois, United States
- Contact708-226-4357
- Patrick A. Hagen · Principal investigator
Recruiting
Cancer Care Center of O'Fallon
O'Fallon, Illinois, United States
- Contact217-876-4762 morganthaler.jodi@mhsil.com
- Bryan A. Faller · Principal investigator
Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois, United States
- Contact217-545-7929
- Bryan A. Faller · Principal investigator
Recruiting
Springfield Clinic
Springfield, Illinois, United States
- Contact800-444-7541
- Bryan A. Faller · Principal investigator
Recruiting
Springfield Memorial Hospital
Springfield, Illinois, United States
- Contact217-528-7541 pallante.beth@mhsil.com
- Bryan A. Faller · Principal investigator
Recruiting
Carle Cancer Center
Urbana, Illinois, United States
- Contact800-446-5532 Research@carle.com
- Priyank P. Patel · Principal investigator
Recruiting
Mary Greeley Medical Center
Ames, Iowa, United States
- Contact515-956-4132
- Joseph J. Merchant · Principal investigator
Recruiting
McFarland Clinic - Ames
Ames, Iowa, United States
- Contact515-239-4734 ksoder@mcfarlandclinic.com
- Joseph J. Merchant · Principal investigator
Recruiting
McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa, United States
- Contact515-956-4132
- Joseph J. Merchant · Principal investigator
Recruiting
McFarland Clinic - Marshalltown
Marshalltown, Iowa, United States
- Contact515-956-4132
- Joseph J. Merchant · Principal investigator
Recruiting
Lahey Clinic
Burlington, Massachusetts, United States
- Contact781-744-3421 lhmc-cancer-clinical-trials@lahey.org
- Julio Hajdenberg · Principal investigator
Recruiting
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health Medical Center - Brighton
Brighton, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan, United States
- Contact313-916-3721 CTOResearch@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health Medical Center - Canton
Canton, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Chelsea Hospital
Chelsea, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Hematology Oncology Consultants-Clarkston
Clarkston, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan, United States
- Contact313-916-3721 CTOResearch@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
Henry Ford Medical Center-Fairlane
Dearborn, Michigan, United States
- Contact313-916-3721 CTOResearch@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
- Contact800-527-6266 ctoadmin@karmanos.org
- Andrew Kin · Principal investigator
Recruiting
Henry Ford Hospital
Detroit, Michigan, United States
- Contact313-916-3721 CTOResearch@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States
- Contact313-576-9790 ctoadmin@karmanos.org
- Andrew Kin · Principal investigator
Recruiting
Cancer Hematology Centers - Flint
Flint, Michigan, United States
- Contact810-762-8038 wstrong@ghci.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Genesys Hurley Cancer Institute
Flint, Michigan, United States
- Contact810-762-8038 wstrong@ghci.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Hurley Medical Center
Flint, Michigan, United States
- Contact810-762-8038 wstrong@ghci.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Allegiance Health
Jackson, Michigan, United States
- Contact313-916-3721 CTOResearch@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
University of Michigan Health - Sparrow Lansing
Lansing, Michigan, United States
- Contact517-364-3712 harsha.trivedi@umhsparrow.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Henry Ford Medical Center-Columbus
Novi, Michigan, United States
- Contact313-916-3721 CTOResearch@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
Michigan Healthcare Professionals Pontiac
Pontiac, Michigan, United States
- Contact248-858-6215 Emily.Crofts@trinity-health.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health IHA Medical Group-Alice Gustafson Center
Pontiac, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
MyMichigan Medical Center Saginaw
Saginaw, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
MyMichigan Medical Center Tawas
Tawas City, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan, United States
- Contact313-916-3721 CTOResearch@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
Henry Ford Wyandotte Hospital
Wyandotte, Michigan, United States
- Contactnhay@hfhs.org
- Vijayalakshmi Donthireddy · Principal investigator
Recruiting
Huron Gastroenterology PC
Ypsilanti, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan, United States
- Contact734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Mercy Hospital
Coon Rapids, Minnesota, United States
- Contact952-993-1517 mmcorc@healthpartners.com
- David M. King · Principal investigator
Recruiting
Minnesota Oncology - Edina
Edina, Minnesota, United States
- Contact952-993-1517 mmcorc@healthpartners.com
- David M. King · Principal investigator
Recruiting
Abbott-Northwestern Hospital
Minneapolis, Minnesota, United States
- Contact952-993-1517 mmcorc@healthpartners.com
- David M. King · Principal investigator
Recruiting
Hennepin County Medical Center
Minneapolis, Minnesota, United States
- Contact952-993-1517 mmcorc@healthpartners.com
- David M. King · Principal investigator
Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Contact855-776-0015
- Sikander Ailawadhi · Principal investigator
Recruiting
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, United States
- Contact952-993-1517 mmcorc@healthpartners.com
- David M. King · Principal investigator
Recruiting
Regions Hospital
Saint Paul, Minnesota, United States
- Contact952-993-1517 mmcorc@healthpartners.com
- David M. King · Principal investigator
Recruiting
United Hospital
Saint Paul, Minnesota, United States
- Contact952-993-1517 mmcorc@healthpartners.com
- David M. King · Principal investigator
Recruiting
Saint Francis Medical Center
Cape Girardeau, Missouri, United States
- Contact573-334-2230 sfmc@sfmc.net
- Bryan A. Faller · Principal investigator
Recruiting
Heartland Regional Medical Center
Saint Joseph, Missouri, United States
- Contact816-271-7937 Trisha.England2@mymlc.com
- Jay W. Carlson · Principal investigator
Recruiting
Mercy Hospital South
St Louis, Missouri, United States
- Contact314-525-6042 Danielle.Werle@mercy.net
- Jay W. Carlson · Principal investigator
Recruiting
Saint Vincent Frontier Cancer Center
Billings, Montana, United States
- Contact800-648-6274
- Patrick W. Cobb · Principal investigator
Recruiting
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
- Contact212-639-7592
- Maria L. Palomba · Principal investigator
Recruiting
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
- Contact212-639-7592
- Maria L. Palomba · Principal investigator
Recruiting
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
- Contact212-639-7592
- Maria L. Palomba · Principal investigator
Recruiting
Memorial Sloan Kettering Commack
Commack, New York, United States
- Contact212-639-7592
- Maria L. Palomba · Principal investigator
Recruiting
Memorial Sloan Kettering Westchester
Harrison, New York, United States
- Contact212-639-7592
- Maria L. Palomba · Principal investigator
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Contact212-639-7592
- Maria L. Palomba · Principal investigator
Recruiting
University of Rochester
Rochester, New York, United States
- Contact585-275-5830
- Clive S. Zent · Principal investigator
Recruiting
Memorial Sloan Kettering Nassau
Uniondale, New York, United States
- Contact212-639-7592
- Maria L. Palomba · Principal investigator
Recruiting
Wilmot Cancer Institute at Webster
Webster, New York, United States
- ContactWCICTOresearch@urmc.rochester.edu
- Clive S. Zent · Principal investigator
Recruiting
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, United States
- Contact800-804-9376
- Manisha Bhutani · Principal investigator
Recruiting
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, United States
- Contact919-587-9084 jfields@cancersmoc.com
- Samer S. Kasbari · Principal investigator
Recruiting
Levine Cancer Institute-Gaston
Gastonia, North Carolina, United States
- Contact800-804-9376
- Manisha Bhutani · Principal investigator
Recruiting
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, United States
- Contact919-587-9084 jfields@cancersmoc.com
- Samer S. Kasbari · Principal investigator
Recruiting
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, United States
- Contact910-587-9084 jfields@cancersmoc.com
- Samer S. Kasbari · Principal investigator
Recruiting
Atrium Health Union/LCI-Union
Monroe, North Carolina, United States
- Contact980-442-2000
- Manisha Bhutani · Principal investigator
Recruiting
Licking Memorial Hospital
Newark, Ohio, United States
- Contact614-488-2745 Jeffh@columbusccop.org
- Aruna C. Gowda · Principal investigator
Recruiting
Saint Alphonsus Cancer Care Center-Baker City
Baker City, Oregon, United States
- Contact406-969-6060 mccinfo@mtcancer.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Providence Newberg Medical Center
Newberg, Oregon, United States
- Contact503-215-2614 CanRsrchStudies@providence.org
- Charles W. Drescher · Principal investigator
Recruiting
Saint Alphonsus Cancer Care Center-Ontario
Ontario, Oregon, United States
- Contact406-969-6060 mccinfo@mtcancer.org
- Tareq Al baghdadi · Principal investigator
Recruiting
Providence Willamette Falls Medical Center
Oregon City, Oregon, United States
- Contact503-215-2614 CanRsrchStudies@providence.org
- Charles W. Drescher · Principal investigator
Recruiting
Providence Portland Medical Center
Portland, Oregon, United States
- Contact503-215-2614 CanRsrchStudies@providence.org
- Charles W. Drescher · Principal investigator
Recruiting
Providence Saint Vincent Medical Center
Portland, Oregon, United States
- Contact503-215-2614 CanRsrchStudies@providence.org
- Charles W. Drescher · Principal investigator
Recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, United States
- Contact804-628-6430 CTOclinops@vcu.edu
- Bharadhwaj Kolipakkam · Principal investigator
Recruiting
Swedish Cancer Institute-Edmonds
Edmonds, Washington, United States
- Contact206-215-2343 PCRC-NCORP@Swedish.org
- Charles W. Drescher · Principal investigator
Recruiting
Swedish Cancer Institute-Issaquah
Issaquah, Washington, United States
- Contact206-215-2343 PCRC-NCORP@Swedish.org
- Charles W. Drescher · Principal investigator
Recruiting
Swedish Medical Center-First Hill
Seattle, Washington, United States
- Contact206-215-2343 PCRC-NCORP@Swedish.org
- Charles W. Drescher · Principal investigator
Recruiting
ThedaCare Regional Cancer Center
Appleton, Wisconsin, United States
- Contact920-364-3604 ResearchDept@thedacare.org
- Yazhini Vallatharasu · Principal investigator
Recruiting
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, United States
- Contact608-775-2385 cancerctr@gundersenhealth.org
- David E. Marinier · Principal investigator
Recruiting
Marshfield Medical Center-River Region at Stevens Point
Stevens Point, Wisconsin, United States
- Contact800-782-8581 oncology.clinical.trials@marshfieldresearch.org
- Adedayo A. Onitilo · Principal investigator
Recruiting
Marshfield Medical Center - Weston
Weston, Wisconsin, United States
- Contact800-782-8581 oncology.clinical.trials@marshfieldresearch.org
- Adedayo A. Onitilo · Principal investigator
Recruiting
McFarland Clinic - Boone
Boone, Iowa, United States
Suspended
McFarland Clinic - Jefferson
Jefferson, Iowa, United States
Suspended
Newland Medical Associates-Clarkston
Clarkston, Michigan, United States
Suspended
Genesee Hematology Oncology PC
Flint, Michigan, United States
Suspended
Oncology Hematology Associates of Saginaw Valley PC
Saginaw, Michigan, United States
Suspended
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
Active, not recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
Active, not recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Active, not recruiting
Siteman Cancer Center-South County
St Louis, Missouri, United States
Active, not recruiting
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, United States
Active, not recruiting
Glens Falls Hospital
Glens Falls, New York, United States
Active, not recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Active, not recruiting
Strecker Cancer Center-Belpre
Belpre, Ohio, United States
Suspended
Adena Regional Medical Center
Chillicothe, Ohio, United States
Suspended
Mount Carmel East Hospital
Columbus, Ohio, United States
Suspended
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, United States
Suspended
Riverside Methodist Hospital
Columbus, Ohio, United States
Suspended
Grant Medical Center
Columbus, Ohio, United States
Suspended
The Mark H Zangmeister Center
Columbus, Ohio, United States
Suspended
Mount Carmel Health Center West
Columbus, Ohio, United States
Suspended
Doctors Hospital
Columbus, Ohio, United States
Suspended
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, United States
Suspended
Grady Memorial Hospital
Delaware, Ohio, United States
Suspended
Dublin Methodist Hospital
Dublin, Ohio, United States
Suspended
Central Ohio Breast and Endocrine Surgery
Gahanna, Ohio, United States
Suspended
Mount Carmel Grove City Hospital
Grove City, Ohio, United States
Suspended
Fairfield Medical Center
Lancaster, Ohio, United States
Suspended
Saint Rita's Medical Center
Lima, Ohio, United States
Suspended
OhioHealth Mansfield Hospital
Mansfield, Ohio, United States
Suspended
Marietta Memorial Hospital
Marietta, Ohio, United States
Suspended
OhioHealth Marion General Hospital
Marion, Ohio, United States
Suspended
Knox Community Hospital
Mount Vernon, Ohio, United States
Suspended
Newark Radiation Oncology
Newark, Ohio, United States
Suspended
Mercy Health - Perrysburg Hospital
Perrysburg, Ohio, United States
Suspended
Southern Ohio Medical Center
Portsmouth, Ohio, United States
Suspended
Mercy Health - Saint Vincent Hospital
Toledo, Ohio, United States
Suspended
Mercy Health - Saint Anne Hospital
Toledo, Ohio, United States
Suspended
Saint Ann's Hospital
Westerville, Ohio, United States
Suspended
Genesis Healthcare System Cancer Care Center
Zanesville, Ohio, United States
Suspended
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, United States
Suspended
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, United States
Active, not recruiting
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, United States
Active, not recruiting
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin, United States
Active, not recruiting
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, United States
Active, not recruiting

Comparing venetoclax with rituximab and ibrutinib with rituximab or zanubrutinib for untreated Waldenström's macroglobulinemia

What this study is

What's being tested

Study details

Who can join

Monitoring & Endpoints

Study locations (150)

Study team

National Cancer Institute (NCI)

Sikander Ailawadhi

Frequently asked questions